Tear Sheet

Company Overview

HTG Molecular Diagnostics, Inc's. (“HTG”) mission is to empower precision medicine at the local level. In 2013, the company commercialized its HTG Edge instrument platform and a portfolio of multiplexed profiling panels that leverage HTG’s proprietary target protection chemistry. In 2014, the company launched the HTG EdgeSeq system that combines the power of HTG Edge chemistry and automation with NGS technology. The HTG EdgeSeq system enables fast and easy use of NGS instruments for molecular profiling.

Stock Quote

Copyright Nasdaq. Minimum 15 minutes delayed.

News Releases

Date Title and Summary
Toggle Summary HTG Molecular Diagnostics Adds Three Executive Team Members
February 13, 2012 TUCSON, Ariz. — HTG Molecular , a privately-held, Tucson-based provider of molecular-technology solutions, added three industry-renown professionals to its executive team: Shaun McMeans , Vice President of Finance, Administration and Chief Financial Officer; Timothy J Holzer,
Toggle Summary HTG/Sanofi US Annouce Biomarker Collaboration
HTG Molecular Diagnostics and Sanofi US Collaborate to Identify B-cell Malignancy Biomarkers Development of tests that help identify patients most likely to respond to targeted therapy is a key step toward the personalization of medicine TUCSON, Ariz.
Toggle Summary HTG Molecular Diagnostics Hires Vice President of Medical Innovation
TUCSON, Ariz. (April 26, 2012) – HTG Molecular Diagnostics, a privately-held, Tucson-based provider of molecular-technology solutions, hired Chris Roberts as vice president of medical innovation. Roberts joins HTG from Caris Life Sciences where he served as vice president of the oncology division
Toggle Summary Sam Rua HTG Molecular Diagnostics VP of Regulatory Affairs is Keynote Presenter at TIDES Conference
TUCSON, Ariz. (May 14, 2012) – Sam Rua, vice president of regulatory affairs and quality systems at HTG Molecular Diagnostics, will offer a keynote presentation, “Update on Commercialization of RUO and IUO Products and Oversight of Lab-Developed Tests,” at the 2012 TIDES Oligonucleotide and Peptide
Toggle Summary HTG Molecular Diagnostics Partners with John Wayne Cancer Institute to Commercialize Melanoma Signatures
TUCSON, Ariz. (June 1, 2012) – The John Wayne Cancer Institute (JWCI) at Saint John’s Health Center in Santa Monica, California selected HTG Molecular Diagnostics as an exclusive commercialization partner for recently identified HTG melanoma signature assays which may be useful for diagnostic and

Stock Chart

SEC Filings

Filing date Description

Annual report which provides a comprehensive overview of the company for the past year

Report of unscheduled material events or corporate event

Report of unscheduled material events or corporate event

An amendment to a SC 13D filing

An amendment to the SC 13G filing